Prostate morbidityLate toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy
Section snippets
Study design and patient selection
We performed a retrospective study of patients with localized prostate cancer at our institution, comparing all those who received 74 Gy without fiducial markers in 2006 (our standard regimen at this time) versus all those who received our updated regimen of 78 Gy with FMIGRT in 2008. Patients who were treated in 2007 were not considered for this study due to it being a changeover year during which our new FMIGRT regimen was phased in. Patients were excluded from the analysis if they had nodal
Patient characteristics
324 patients were identified who received 74 Gy without FMIGRT in 2006. Twelve patients were excluded due to having no follow up data and a further one patient excluded due to incomplete disease details making a total cohort of 311 patients in the non-FMIGRT group. In 2008, there were 251 patients who received 78 Gy with FMIGRT. Six of these were excluded due to no follow up and two patients had incomplete data resulting in a total of 243 patients in the FMIGRT cohort.
Baseline demographics and
Discussion
This study demonstrates that patients treated with FMIGRT have a significantly reduced likelihood of experiencing moderate/severe late gastrointestinal toxicity and a reduced duration of moderate/severe late genitourinary toxicities. These statistically significant reductions were seen even despite patients in the FMIGRT group being dose escalated to 78 Gy compared to those patients in the non-FMIGRT group receiving 74 Gy. These findings are in keeping with what would be expected from the more
Conflict of interest
None.
References (24)
- et al.
Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer
Radiother Oncol
(2007) - et al.
Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial
Int J Radiat Oncol Biol Phys
(2002) - et al.
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
Lancet Oncol
(2007) - et al.
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial
Lancet
(1999) - et al.
Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer
Radiother Oncol
(2007) - et al.
Image-guided radiotherapy: rationale, benefits, and limitations
Lancet Oncol
(2006) - et al.
Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials
Radiother Oncol
(2003) - et al.
Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment
Int J Radiat Oncol Biol Phys
(2009) - et al.
Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery
Int J Radiat Oncol Biol Phys
(2004)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference
Int J Radiat Oncol Biol Phys
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose–volume analysis of a phase II dose-escalation study
Int J Radiat Oncol Biol Phys
Cited by (52)
The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis
2023, Clinical and Translational Radiation OncologyKilovoltage intrafraction monitoring during normofractionated prostate cancer radiotherapy
2020, Cancer/RadiotherapieCitation Excerpt :In this setting, the tumor control probability is correlated to the biologically equivalent dose [1] and dose escalation has been shown to improve clinical progression-free survival in several randomized trials [2–6]. Escalating the dose to the prostatic gland however requires the use of intensity-modulated radiotherapy (IMRT) with image-guided radiation therapy (IGRT) in order to spare the surrounding structures and decrease treatment-related toxicity [7–9]. During EBRT, the prostate position uncertainty is due both to interfraction motion following patient-specific anatomical changes and set-up uncertainties, and intrafraction motion.
ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer
2019, Radiotherapy and OncologyModalities and techniques used for stereotactic radiotherapy, intensity-modulated radiotherapy, and image-guided radiotherapy: A 2018 survey by the Japan Society of Medical Physics
2019, Physica MedicaCitation Excerpt :The current status of radiotherapy in Japan appears similar to that of the US a decade ago. Several studies have shown that IGRT significantly decreased rectal and bladder toxicity in prostate radiotherapy [8,10,32,33]. A phase 3 clinical trial of prostate radiotherapy also showed that daily IGRT significantly decreased the risks of biochemical recurrence and rectal toxicity compared with weekly IGRT [9].
Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial
2018, International Journal of Radiation Oncology Biology PhysicsDaily IGRT for prostate cancer: Can we stop the train?
2018, Radiotherapy and Oncology